By Rick Pezzullo— Tarrytown-based Regeneron Pharmaceuticals, Inc. announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV™, an antibody cocktail used as a passive vaccine for the prevention of COVID-19 in people at high risk of infection due to household exposure to a COVID-19 patient. The trial is being run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). “These data using REGEN-COV as a passive vaccine suggest that it may both […]
The post Regeneron Reports Positive Data with Antibody Cocktail Used to Prevent COVID-19 appeared first on The Hudson Independent Community News -.